We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Requests Hearing to Fight FDA’s Withdrawal of Avastin’s Breast Cancer Indication
Genentech Requests Hearing to Fight FDA’s Withdrawal of Avastin’s Breast Cancer Indication
January 21, 2011
Genentech has appealed an FDA recommendation to withdraw Avastin’s indication as a metastatic breast cancer (MBC) treatment, claiming the oncologic delays progression of the disease by a significant amount of time.